Mustang Bio, Inc. (MBIO)
- Previous Close
1.2400 - Open
1.1700 - Bid --
- Ask --
- Day's Range
1.1200 - 1.2200 - 52 Week Range
1.1200 - 65.0000 - Volume
851,306 - Avg. Volume
466,028 - Market Cap (intraday)
4.099M - Beta (5Y Monthly) 2.14
- PE Ratio (TTM)
-- - EPS (TTM)
-8.6000 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
www.mustangbio.comRecent News: MBIO
View More
Performance Overview: MBIO
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBIO
View MoreValuation Measures
Market Cap
4.03M
Enterprise Value
-1.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-58.01%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.75M
Diluted EPS (ttm)
-8.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.84M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.83M